Odyssey Therapeutics, Inc. Common Stock (ODTX)

BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)

Headquarters: United States
Market Cap: $1.0B

About Odyssey Therapeutics, Inc. Common Stock

Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases. The Company is developing medicines that are designed to precisely target disease pathology with an initial emphasis on the innate immune system. Its programs include OD-07656, a small molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, a small molecule scaffolding inhibitor of interleukin-1 receptor-associated kinase 4, or IRAK4, and OD-00910, an agonistic protein therapeutic targeting tumor necrosis factor receptor 2, or TNFR2, built from camelid heavy chain variable regions, or VHH, domains.

SentiSense also tracks daily options readings for Odyssey Therapeutics, Inc. Common Stock: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.

Odyssey Therapeutics, Inc. Common Stock stock analysis, sentiment tracking, and market intelligence on SentiSense.